D. Balli

发表

MYC controls metastatic heterogeneity in pancreatic cancer

S. Lowe, C. Iacobuzio-Donahue, P. Raman, 2021, bioRxiv.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition

J. Whitsett, T. Kalin, V. Kalinichenko, 2013, The EMBO journal.

Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens

J. Johnston, J. DeVoss, J. Lesch, 2020, bioRxiv.

Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway

T. Kalin, V. Kalinichenko, X. Ren, 2020, PLoS genetics.

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Katie M. Campbell, Christopher A. Miller, Brian J. Stevenson, 2020, Cell.

Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome

A. Madabhushi, D. Rimm, K. Schalper, 2022, npj Precision Oncology.

Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

S. Lowe, J. Tobias, L. Coussens, 2018, Immunity.

Microenvironment and Immunology Endothelial Cell – Specific Deletion of Transcription Factor FoxM 1 Increases Urethane-Induced Lung Carcinogenesis

T. Kalin, V. Kalinichenko, Yufang Zhang, 2010 .

FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas

A. Warth, H. Dienemann, J. Whitsett, 2017, PLoS genetics.

Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.

T. Chan, Han Chang, P. Fu, 2022, JCO precision oncology.

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer

H. Ishwaran, K. Nathanson, B. Stanger, 2018, Cancer Immunology Research.

Deletion of Forkhead Box M1 Transcription Factor from Respiratory Epithelial Cells Inhibits Pulmonary Tumorigenesis

J. Whitsett, T. Kalin, V. Kalinichenko, 2009, PloS one.

EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration.

E. Furth, D. Bar-Sagi, Amine Sahmoud, 2018, Developmental cell.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.

A. Mansfield, A. Tsao, P. Baas, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

B. Stanger, R. Vonderheide, A. Rech, 2016, Clinical Cancer Research.

MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

S. Lowe, C. Iacobuzio-Donahue, P. Raman, 2021, Cancer discovery.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Anil Vachani, Charu Aggarwal, Andrea B. Troxel, 2016, Clinical Cancer Research.

An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters

F. Tong, Liping Yu, Keely A. Dulmage, 2018, Scientific Reports.

Endothelial cell-specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis.

T. Kalin, V. Kalinichenko, Yufang Zhang, 2011, Cancer research.

RESULTS Foxm 1 deficiency in myeloid cells does not alter the number of macrophages in untreated lungs

T. Kalin, V. Kalinichenko, X. Ren, 2016 .

Foxm1 Transcription Factor is required for Macrophage Migration during Lung Inflammation and Tumor Formation

T. Kalin, V. Kalinichenko, X. Ren, 2011, Oncogene.

Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis*

Yuqi Cai, T. Kalin, S. Waltz, 2013, The Journal of Biological Chemistry.

Calcium signaling induces a partial EMT

B. Freedman, A. Rustgi, D. Lyden, 2021, EMBO reports.

LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

A. Mansfield, S. Peters, A. Tsao, 2021, Annals of Oncology.

An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters

Ling Wang, Charles H Pletcher, Liping Yu, 2018, Scientific Reports.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

A. Madabhushi, D. Rimm, K. Schalper, 2023, NPJ precision oncology.

Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation.

C. Rudin, M. Hellmann, J. Poirier, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.

J. Neely, M. Sausen, G. Green, 2021 .

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

N. Reinmuth, Ying Cheng, T. John, 2023, Journal of Clinical Oncology.

84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816

S. Broderick, T. Mitsudomi, J. Neely, 2023, Journal of Thoracic Oncology.

Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis*

Yuqi Cai, S. Waltz, S. Kasper, 2013, The Journal of Biological Chemistry.